Tegoprazan

Tegoprazan
Product Description

Tegoprazan is a novel patented Potassium-Competitive Acid Blocker (P-CAB) which alleviates the limitations of the historical Proton Pump Inhibitors (PPIs) and of other competing P-CABs. 

Tegoprazan's competitive advantages have been demonstrated via Phase 3 clinical studies conducted in Korea and Phase 1 clinical study from the US. 


Based on the outstanding achievements, Tegoprazan was approved by MFDS in 2019 under four (4) indications: Erosive Reflux Disease (ERD), Non-Erosive Gastro Esophageal Reflux Disease (NERD), Gastric Ulcer (GU) and Helicobacter pylori Eradication. 


Other than in South Korea, Tegoprazan received approval in China, Mongolia and Philippines among the 34 countries where HK inno.N has licensed out to.


HK inno.N is actively searching for business partners whom they can develop Tegoprazan in unpartnered counties. For further information, please contact Ga-Young Lee (BD, [email protected])

Read more Show less

HK inno.N Corporation

  • KR
  • 2020
    On CPHI since
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less

HK inno.N Corporation

  • KR
  • 2020
    On CPHI since
Company types
Pharmaceutical company
View company profile

More Products from HK inno.N Corporation (23)

show all 23 other products

HK inno.N Corporation resources (1)

  • HK inno.N Corporation receives regulatory approval for first novel drug

    News HK inno.N Corporation receives regulatory approval for first novel drug

    Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)
    24 Sep 2020